An urgent proposal for the immediate use of melatonin as an adjuvant to anti- SARS-CoV-2 vaccination
Competition among pharmaceutical companies to develop safe and effective vaccines against SARS-CoV-2 is high. However, based on the prior experience with the influenza vaccine, up to 50% in lack of effectiveness would be found among healthy adults receiving effective vaccines against SARS-CoV-2.